



BRIDGE Study

Bridging Knowledge and Access to Genetic Services

Version 1.0 | April 2026

General Information

Cancer care in Kenya is evolving, and genetic testing is becoming increasingly important for guiding treatment. However, access and use of BRCA genetic services remain limited. The aim of this research is to map current practices in **BRCA genetic counselling and testing across Kenya**. Hereditary Breast and Ovarian Cancer (HBOC) accounts for a significant proportion of cancer risk driven by BRCA1/2 mutations, underscoring the need for context-specific genetic services.

The findings from this national baseline survey will inform the development of targeted interventions to strengthen genetic service delivery, improve access to BRCA testing, and enhance cancer care outcomes across Kenya.

We appreciate your interest in participating in this online survey. You are invited to take part if you are a healthcare professional currently involved, or have been involved, in cancer care in Kenya. Please read through this information before agreeing to participate.

You may ask any questions before deciding to take part by contacting the research team using the details provided at the end of this document.

What will I be asked to do?

You will be asked to complete an anonymous online questionnaire about your views, experiences, and current practices regarding BRCA genetic counselling and testing. This should take approximately

10 minutes to complete. There are no right or wrong answers; we are interested in your honest professional opinions.

The research team will use the data for analysis and may share anonymised data with trusted collaborators as set out below.



Who can participate?

You are invited to take part if you are a healthcare professional in Kenya involved in cancer care, including:

- Oncologists
- Obstetricians & Gynaecologists
- Surgeons
- Oncology Nurses
- Oncology Clinical Officers

Why you were selected

You are being invited because of your role in providing cancer care in Kenya and your experience is essential in shaping future services.

Do I have to take part?

No. Please note that participation is entirely **voluntary**. If you do decide to take part, you may withdraw at any point for any reason before submitting your answers.

How will my data be used?

We will take all reasonable measures to ensure that data remain confidential.

We will ask a small number of demographic questions, including your professional role, years of experience, and region of practice.

The responses you provide will be stored in a password-protected electronic file on secure servers and may be used in academic publications, conference presentations, and public summaries. Research data will be stored for as long as they continue to have value to the research community, with a minimum of three years after publication or public release of the research.

Who will have access to my data?

The BRIDGE Study research team is the data controller with respect to any personal data and, as such, will determine how your personal data are used in the research. The research team will process your personal data for the purpose of the research outlined above.

The data you provide may be shared with named collaborators for the purposes of secure storage, analysis, and dissemination. If we use the data in future studies or share data with other researchers, only anonymised data will be shared. Any dataset



Bridging Knowledge and Access to Genetic Services



made public will have identifying information removed and free text reviewed to minimise any risk of re-identification.

What are the benefits of taking part?

Participants will receive access to follow-up capacity-building training resources related to genetic counselling and BRCA testing. Your contribution will help identify gaps in genetic service delivery and inform national strategies for improving cancer care in Kenya.

Ethics Approval

This research has been reviewed by, and received ethics clearance through, the relevant institutional ethics committee. Institutional Review & Ethics Committee of Mount Kenya University (IREC approval number 4688). Pan African Clinical Trial Registry (PACTR) registration number PACTR202603791616230. National Commission for Science, Technology, and Innovation (NASCOTI) Kenya License number NACOSTI/P/26/4187133.

Contact Information

If you have any questions about this research or wish to raise a concern, please contact:

Principal Investigator

Dr. Afrin Fatima Shaffi
Gynaecologic Oncologist
BRIDGE Study (in collaboration with GOSK)

Email: bridgegosk@gmail.com

Survey Link: <https://ee-eu.kobotoolbox.org/x/KPdY7CZg>